Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Oct;102(4):595-599.e1.
doi: 10.1016/j.gie.2025.02.020. Epub 2025 Feb 19.

Safety of same-day discharge after gastric peroral endoscopic myotomy in patients with refractory gastroparesis: an international multicenter study

Marita Salame  1 , Yervant Ichkhanian  1 , Nwal Hadaki  1 , John M Wo  1 , Sarah A Stainko  1 , Akira Saito  1 , Robert M Siwiec  1 , Thomas V Nowak  1 , Andrew Li  2 , Joo Ha Hwang  2 , Juliana Yang  3 , Joseph Broucek  4 , Tuba Esfandyari  5 , Stephanie Joseph  6 , Michael Ujiki  6 , Ashley E Williams  7 , Jacob R Moremen  7 , Zane Gouda  8 , Alexander Schlachterman  8 , Kristina Hugova  9 , Jan Martinek  9 , Calvin X Geng  10 , Alexander Podboy  10 , Andrew Y Wang  10 , Michael Lajin  11 , Payton Miller  1 , Lennon Gregor  1 , Hashem Albunni  1 , John M Dewitt  1 , Mohammad A Al-Haddad  12
Affiliations
Multicenter Study

Safety of same-day discharge after gastric peroral endoscopic myotomy in patients with refractory gastroparesis: an international multicenter study

Marita Salame et al. Gastrointest Endosc. 2025 Oct.

Abstract

Background and aims: The postoperative management of gastric peroral endoscopic myotomy (G-POEM) lacks standardization. This study aimed to evaluate adverse events, readmission rates, and feasibility of same-day discharge (SDD) after G-POEM.

Methods: A multicenter retrospective review of prospectively collected G-POEM data was conducted. The primary outcome was the 15-day readmission rates in SDD and admitted patients. Secondary outcomes included readmission risk factors, clinical success, and adverse events (AEs).

Results: We found a 4.1% 15-day readmission rate in 482 patients (95% CI, 3.2%-5.4%). SDD clinical success rates at 6 to 12 months were 54.1% versus 59.7% for the admitted group. The overall AE rate was 4.1%. SDD patients tended to have shorter procedure times and higher frequencies of double myotomy and endoscopic suturing for closure.

Conclusions: G-POEM is safe with low incidence of AEs and 15-day readmission rates. SDD appears safe in uncomplicated cases, suggesting that upper gastrointestinal studies after G-POEM may be unnecessary.

Clinicaltrials: gov (NCT04434781).

PubMed Disclaimer

Conflict of interest statement

Disclosure The following authors disclosed financial relationships: T. Nowak: Principal investigator on a research study for Enterra. J. H. Hwang: Consultant for Olympus, Boston Scientific, Medtronic, FujiFilm, Erbe, and Micro-Tech. M. Lajin: Subinvestigator to Fractyl Health (pending status). M. Ujiki: Consultant for Boston Science and Olympus; speaker for Gore Medical. J. M. DeWitt: Consultant for Boston Scientific and Olympus. M. A. Al-Haddad: Consultant for Boston Scientific and Interpace Diagnostics; research support from Amplified Sciences. All other authors disclosed no financial relationships.

Publication types

Associated data